Not Yet Recruiting
Tislelizumab Plus Chemotherapy and BACE for Unresectable NSCLC
NCT07561983
- Conditions
- Chemoembolization, Therapeutic, Chemotherapy, Conversion Therapy, +2 more
- Locations
-
- Sichuan Cancer Hospital and Research Institute Chengdu, Sichuan, China